Pyrantel


Generic Medicine Info
Indications and Dosage
Oral
Ascariasis
Adult: Doses are expressed as pyrantel base. Alternative agent: Usual dose: 10-11 mg/kg as a single dose. Max: 1,000 mg/dose.

Oral
Enterobiasis
Adult: Doses are expressed as pyrantel base. Usual dose: 10-11 mg/kg as a single dose, repeated after 2 weeks to prevent reinfection. Max: 1,000 mg/dose.
Child: ≥2 years Same as adult dose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Patient with severe malnutrition, dehydration or anaemia. Hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Gastrointestinal disorders: Nausea, vomiting, abdominal pain or cramps, diarrhoea.
Investigations: Transient increase in liver enzymes, particularly AST.
Metabolism and nutrition disorders: Anorexia.
Nervous system disorders: Dizziness, headache, drowsiness.
Skin and subcutaneous tissue disorders: Rash.
Monitoring Parameters
Monitor stool for the presence of worms, eggs, and occult blood.
Drug Interactions
May antagonise the effects of piperazine, and vice versa.
Action
Description: Pyrantel is a pyrimidine-derivative anthelmintic agent that acts as a depolarising neuromuscular blocker. It provides its anthelmintic effect by releasing acetylcholine and inhibiting cholinesterase, thereby stimulating the ganglionic (nicotinic) receptors of susceptible helminths. This activity results in the paralysis and detachment of helminths that can be expelled from the gastrointestinal tract via normal peristalsis.
Pharmacokinetics:
Absorption: Poorly and incompletely absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1-3 hours.
Metabolism: Partially metabolised in the liver.
Excretion: Via faeces (<50% as unchanged drug); urine (approx 7% as unchanged drug and metabolites).
Chemical Structure

Chemical Structure Image
Pyrantel

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 708857, Pyrantel. https://pubchem.ncbi.nlm.nih.gov/compound/Pyrantel. Accessed Aug. 26, 2021.

Storage
Store between 15-30°C.
MIMS Class
Anthelmintics
ATC Classification
P02CC01 - pyrantel ; Belongs to the class of tetrahydropyrimidine derivative agents. Used as antinematodal.
References
Anon. Pyrantel Pamoate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/08/2021.

Anon. Pyrantel. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 06/08/2021.

Buckingham R (ed). Pyrantel Embonate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/08/2021.

Combantrin (Johnson & Johnson [Phils.] Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 06/08/2021.

Pyrantel Pamoate Suspension (Jefferson Labs). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/08/2021.

Pyrantel Pamoate Tablet (ProMex LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/08/2021.

Pyrantel. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 06/08/2021.

Pyrapam (General Drugs House Co Ltd). MIMS Thailand. http://www.mims.com/thailand. Accessed 06/08/2021.

Disclaimer: This information is independently developed by MIMS based on Pyrantel from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in